# US 2006/0135438 A1 · Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0135438 A1
- Document ID: US20060135438A1
- Status: Published application
- Kind: A1
- Application number: 11/285,754
- Filed: 2005-11-22
- Published: 2006-06-22
- Earliest claimed: 2004-12-03
- Assignees: The Curators of the University of Missouri
- Inventors: Ashim Mitra; Soumyajit Majumdar; Ritesh Jain; Yasser Nashed
- Web page: https://patentgrep.com/patent/US20060135438A1

## CPC

- A61K 38/04: Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55})
- C07K 5/06026: {the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala}
- C07K 5/06052: {Val-amino acid}
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Amino acid ester, dipeptide, and tripeptide ester derivatives of bioactive agents are provided wherein said parent agents are substrates effluxed by the P-gp transporter. The derivatives are useful in treating the same condition as the bioactve agent. Also disclosed is a method for preparing a bioactive agent for targeted delivery by nutrient or peptide transporters comprising linking the agent to one or more groups of the formula —X—Y(n)-Z(n′)-Z′(n″)-R; wherein each X, Y, Z, and Z′ is independently Met, Val, Thr, Tyr, Trp, Ser, Ala or Gly; R is independently H or an amino-protecting group; and each n, n′, or n″ is independently 0 or 1.

## Claims

### Claim 1

A compound of formula (I):
DRUG-X-Y(n)-Z(n∝)-Z′(n″)-R (I)
wherein DRUG is a bioactive agent that is a P-glycoprotein substrate; each X, Y, Z, and Z′ is independently Met, Val, Thr, Tyr, Trp, Ser, Ala, or Gly; R is H or an amino-protecting group; and each n, n′, or n″ is independently 0 or 1; or a pharmaceutically acceptable salt thereof, with the proviso that DRUG is not acyclovir or ganciclovir and that DRUG is non-peptidyl.

### Claim 2 (depends on 1)

The compound of claim 1 wherein each X, Y, Z, and Z′ is individually Gly or Val.

### Claim 3 (depends on 1)

The compound of claim 1 wherein R is H, acetyl, or t-butoxycarbonyl.

### Claim 4 (depends on 3)

The compound of claim 3 wherein R is H.

### Claim 5 (depends on 1, 2)

The compound of claim 1 or 2 wherein each of n, n′, and n″ is 0.

### Claim 6 (depends on 1)

The compound of claim 1 wherein the compound is Val-Val-SAQ, Gly-Val-SAQ, Val-Q, or Val-Val-Q, wherein SAQ is saquinavir and Q is quinidine.

### Claim 7 (depends on 1, 6)

A pharmaceutical composition comprising an effective amount of a compound of any one of claims 1 or 6 in combination with a pharmaceutically acceptable carrier, wherein the effective amount is based on the quantity of free drug that is released from the compound, and the compound is effective for the same purpose as the free drug.

### Claim 8 (depends on 7)

The composition of claim 7 wherein the carrier is a liquid.

### Claim 9 (depends on 7)

The composition of claim 7 wherein the carrier is a solid.

### Claim 10

A method of treating a patient for a condition wherein the bioactive agent of choice is DRUG, wherein DRUG is a substrate that is effluxed by the P-gp transporter; comprising administering to the patient an effective amount of a compound of formula (I):
DRUG-X-Y(n)-Z(n′)-Z′(n″)-R (I)
wherein each X, Y, Z, and Z′ is independently Met, Val, Thr, Tyr, Trp, Ser, Ala, or Gly; R is H or an amino-protecting group; and each n, n′, or n″ is independently 0 or 1; or a pharmaceutically acceptable salt thereof, with the proviso that DRUG is not acyclovir or ganciclovir and that DRUG is non-peptidyl.

### Claim 11 (depends on 10)

The method of claim 10 wherein each X, Y, Z, and Z′ is individually Gly or Val.

### Claim 12 (depends on 11)

The method of claim 11 wherein R is H.

### Claim 13 (depends on 10, 11)

The method of claim 10 or 11 wherein each of n, n′, and n″ is 0.

### Claim 14 (depends on 10)

The method of claim 10 further comprising identifying the target cells of patient and/or DRUG as susceptible to efflux of DRUG before administration of the compound of Formula I.

### Claim 15

A method for enhancing delivery to cells of a bioactive agent, wherein said bioactive agent is DRUG, wherein DRUG is effluxed from said cells by the P-gp transporter, comprising administering to the cells an effective amount of a compound of formula (I):
DRUG-X-Y(n)-Z(n″)-Z′(n″)-R (I)
wherein each X, Y, Z, and Z′ is independently Met, Val, Thr, Tyr, Trp, Ser, Ala, or Gly; R is H or an amino-protecting group; and each n, n′, or n″ is independently 0 or 1; or a pharmaceutically acceptable salt thereof, with the proviso that DRUG is not acyclovir or ganciclovir and that DRUG is non-peptidyl.

### Claim 16 (depends on 15)

The method of claim 15 wherein each X, Y, Z, and Z′ is individually Gly or Val.

### Claim 17 (depends on 16)

The method of claim 16 wherein R is H.

### Claim 18 (depends on 15, 16)

The method of claim 15 or 16 wherein each of n, n′, and n″ is 0.

### Claim 19 (depends on 15)

The method of claim 15 further comprising pre-identifying the cells as ones that are expected to efflux DRUG.

### Claim 20

A method of increasing the bioavailability in a mammalian patient of a bioactive agent, wherein said bioactive agent is DRUG, comprising administering to the patient an effective amount of the compound of formula (I):
DRUG-X-Y(n)-Z(n′)-Z′(n″)-R (I)
wherein each X, Y, Z, and Z′ is independently Met, Val, Thr, Tyr, Trp, Ser, Ala, or Gly; R is H or an amino-protecting group; and each n, n′, or n″ is independently 0 or 1; or a pharmaceutically acceptable salt thereof, with the proviso that DRUG is not acyclovir or ganciclovir and that DRUG is non-peptidyl.

### Claim 21 (depends on 20)

The method of claim 20 wherein each X, Y, Z, and Z′ is individually Gly or Val.

### Claim 22 (depends on 21)

The method of claim 21 wherein R is H.

### Claim 23 (depends on 20, 21)

The method of claim 20 or 21 wherein each of n, n′, and n″ is 0.

### Claim 24 (depends on 20)

The method of claim 20 further comprising identifying target cells of the patient and/or drug as susceptible to efflux of DRUG before administration of the compound of formula I.

### Claim 25

A method of increasing the concentration of a bioactive agent in sanctuary sites of a mammalian patient, wherein said bioactive agent is DRUG, comprising administering to the patient an effective amount of the compound of formula (I):
DRUG-X-Y(n)-Z(n′)-Z′(n″)-R (I)
wherein each X, Y, Z, and Z′ is independently Met, Val, Thr, Tyr, Trp, Ser, Ala, or Gly; R is H or an amino-protecting group; and each n, n′, or n″ is independently 0 or 1; or a pharmaceutically acceptable salt thereof, with the proviso that DRUG is not acyclovir or ganciclovir and that DRUG is non-peptidyl.

### Claim 26 (depends on 25)

The method of claim 25 wherein each X, Y, Z, and Z′ is individually Gly or Val.

### Claim 27 (depends on 26)

The method of claim 26 wherein R is H.

### Claim 28 (depends on 25, 26)

The method of claim 25 or 26 wherein each of n, n′, and n″ is 0.

### Claim 29 (depends on 25)

The method of claim 25 further comprising identifying DRUG as an agent that it susceptible to efflux from the sanctuary sites of said patient before administration.

### Claim 30 (depends on 20, 25)

The method of claim 20 or 25 wherein the compound of formula (I) exhibits an affinity for a nutrient transporter that is greater than the affinity of DRUG for said transporter.

### Claim 31 (depends on 30)

The method of claim 30 wherein the nutrient transporter is a peptide transporter.
